Preventing Clinically Important Deterioration of COPD with Addition of Umeclidinium to Inhaled Corticosteroid/Long-Acting β2-Agonist Therapy: An Integrated Post Hoc Analysis

Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial

(2018) Alberto Papi et al.   LANCET

Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD

(2018) David A. Lipson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Association of Cardiovascular Risk With Inhaled Long-Acting Bronchodilators in Patients With Chronic Obstructive Pulmonary Disease

(2018) Meng-Ting Wang et al.   JAMA Internal Medicine

The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD

(2017) Antonio Anzueto et al.   International Journal of Chronic Obstructive Pulmonary Disease

Single inhaler triple therapy versus inhaled corticosteroid plus long-acting β2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial

(2016) Dave Singh et al.   LANCET

A randomized, blinded study to evaluate the efficacy and safety of umeclidinium 62.5 µg compared with tiotropium 18 µg in patients with COPD

(2016) Gregory Feldman et al.   International Journal of Chronic Obstructive Pulmonary Disease

Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol

(2016) Dave Singh et al.   International Journal of Chronic Obstructive Pulmonary Disease

Initiation of triple therapy maintenance treatment among patients with COPD in the US

(2016) Jason Simeone et al.   International Journal of Chronic Obstructive Pulmonary Disease

Bronchodilator reliever use and its association with the economic and humanistic burden of COPD: a propensity-matched study

(2016) Yogesh Suresh Punekar et al.   JOURNAL OF MEDICAL ECONOMICS

Efficacy and Safety of Umeclidinium Added to Fluticasone Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies

(2015) Thomas M. Siler et al.   COPD-Journal of Chronic Obstructive Pulmonary Disease

Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies

(2015) Thomas M. Siler et al.   RESPIRATORY MEDICINE

Global burden of COPD

(2015) José Luis López-Campos et al.   RESPIROLOGY

Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study—a randomised controlled trial

(2015) Peter A Frith et al.   THORAX

Reliever salbutamol use as a measure of exacerbation risk in chronic obstructive pulmonary disease

(2015) Christine R. Jenkins et al.   BMC Pulmonary Medicine

Umeclidinium for treating COPD: an evaluation of pharmacologic properties, safety and clinical use

(2014) Rajapriya Manickam et al.   Expert Opinion On Drug Safety

The Impact of Tiotropium on Mortality and Exacerbations When Added to Inhaled Corticosteroids and Long-Acting β-Agonist Therapy in COPD

(2011) Philip M. Short et al.   CHEST

Seasonality and determinants of moderate and severe COPD exacerbations in the TORCH study

(2011) C. R. Jenkins et al.   EUROPEAN RESPIRATORY JOURNAL

Comparison of resource use by COPD patients on inhaled therapies with long-acting bronchodilators: a database study

(2011) Chris M Kozma et al.   BMC Pulmonary Medicine

Outcomes Associated With Tiotropium Use in Patients With Chronic Obstructive Pulmonary Disease

(2009) Todd A. Lee et al.   ARCHIVES OF INTERNAL MEDICINE

Evaluation of COPD Longitudinally to Identify Predictive Surrogate End-points (ECLIPSE)

(2008) J. Vestbo et al.   EUROPEAN RESPIRATORY JOURNAL

A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease

(2008) Donald P. Tashkin et al.   NEW ENGLAND JOURNAL OF MEDICINE